Bioxytran, Inc.

Yahoo · Aug 4, 2026

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry to

Yahoo · Jul 29, 2026

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate re

Benzinga · Feb 11, 2026

Bioxytran Reports Phase 2 Results Showing 100% Viral Clearance By Day 7 In Randomized Double-Blind Placebo-Controlled ProLectin-M Trial (p=.001)

Yahoo · Feb 4, 2026

Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference

BOSTON, MA / ACCESS Newswire / February 4, 2026 /Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company focused on the development of novel carbohydrate-based therapeutics, today announced that David Platt, Ph.D., Chief Executive Officer ...